13th May 2015 09:20
LONDON (Alliance News) - AstraZeneca PLC on Wednesday said it has entered into a deal with US pharmaceutical company Abbott Laboratories to develop companion diagnostic tests to identify patients with severe asthma most likely to benefit from the tralokinumab biological therapy.
Under the deal, Abbott will develop and commercialise diagnostic tests to measure serum levels of the periostin and DPP4 proteins, which have been identfied as potential predictive biomarkers in patients with severe asthma.
The tests will be developed in conjunction with the phase 3 trial of tralokinumab, a potential asthma treatment developed by AstraZeneca's MedImmune research and development arm.
AstraZeneca shares were up 0.3% to 4,413.00 pence Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca